4.8 Article

Phenotypic and Transcriptomic analysis of Peripheral Blood Plasmacytoid and conventional Dendritic cells in early Drug naive rheumatoid arthritis

Journal

FRONTIERS IN IMMUNOLOGY
Volume 9, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2018.00755

Keywords

rheumatoid arthritis; early rheumatoid arthritis; plasmacytoid dendritic cells; conventional dendritic cells; tolerance

Categories

Funding

  1. Medical Research Council [MR/M003183/1]
  2. JGW Patterson Foundation
  3. Arthritis Research UK [20298]
  4. National Institute for Health Research Newcastle Biomedical Research Center based at Newcastle Hospitals NHS Foundation Trust
  5. Newcastle University
  6. Medical Research Council [MR/M003183/1] Funding Source: researchfish
  7. MRC [G1001518, MR/M003183/1] Funding Source: UKRI

Ask authors/readers for more resources

Objective: Dendritic cells (DCs) are key orchestrators of immune function. To date, rheumatoid arthritis (RA) researchers have predominantly focused on a potential pathogenic role for CD1c+ DCs. In contrast, CD141+ DCs and plasmacytoid DCs (pDCs) have not been systematically examined, at least in early RA. In established RA, the role of pDCs is ambiguous and, since disease duration and treatment both impact RA pathophysiology, we examined pDCs, and CD1c+ and CD141+ conventional DCs (cDCs), in early, drug-naive RA (eRA) patients. Methods: We analyzed the frequency and phenotype of pDCs, CD1c+, and CD141+ DCs from eRA patients and compared findings with healthy controls. In parallel, we performed transcriptional analysis of >600 immunology-related genes (Nanostring) from peripheral blood pDCs, CD1c+ DCs, B cells, T cells, and monocytes. Results: All DC subsets were reduced in eRA (n = 44) compared with healthy controls (n = 30) and, for pDCs, this was most marked in seropositive patients. CD141+ and CD1c+ DCs, but not pDCs, had a comparatively activated phenotype at baseline (increased CD86) and CD1c+ DC frequency inversely associated with disease activity. All DC frequencies remained static 12 months after initiation of immunomodulatory therapy despite a fall in activation markers (e.g., HLA-DR, CD40). There was no association between the whole blood interferon gene signature (IGS) and pDC or CD1c+ DC parameters but an inverse association between CD141+ DC frequency and IGS was noted. Furthermore, IFN-I and IFN-III mRNA transcripts were comparable between eRA pDC and other leukocyte subsets (B cells, CD4+, and CD8+ T cells and monocytes) with no obvious circulating cellular source of IFN-I or IFN-III. Transcriptomic analysis suggested increased pDC and CD1c+ DC proliferation in eRA; pDC differentially expressed genes also suggested enhanced tolerogenic function, whereas for CD1c+ DCs, pro-inflammatory transcripts were upregulated. Discussion: This is the first detailed examination of DC subsets in eRA peripheral blood. Compared with CD1c+ DCs, pDCs are less activated and may be skewed toward tolerogenic functions. CD141+ DCs may be implicated in RA pathophysiology. Our findings justify further investigation of early RA DC biology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Charlotte L. M. Krieckaert, Astrid van Tubergen, Johanna Elin Gehin, Borja Hernandez-Breijo, Guillaume Le Meledo, Alejandro Balsa, Peter Boehm, Sasa Cucnik, Ori Elkayam, Guro L. Goll, Femke Hooijberg, Meghna Jani, Patrick D. W. Kiely, Neil McCarthy, Denis Mulleman, Victoria Navarro-Compan, Katherine Payne, Martin E. Perry, Chamaida Plasencia-Rodriguez, Simon R. Stones, Silje Watterdal Syversen, Annick de Vries, Katherine M. Ward, Gertjan Wolbink, John D. Isaacs

Summary: This study develops EULAR points-to-consider for therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases (RMDs). The points-to-consider are evidence-based and consensus-based statements that highlight the clinical utility of TDM. However, the lack of high quality trials addressing effectiveness and safety of TDM, as well as robust economic evaluation, limits its wider adoption.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B. McInnes, Naveed Sattar, Tanja A. Stamm, Tsutomu Takeuchi, Michael Trauner, Desiree van der Heijde, Marieke Voshaar, Kevin L. Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Ruediger R. Burmester, Johannes W. J. Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H. Choy, Catalin Codreanu, Bernard Combe, Mary K. Crow, Maarten de Wit, Paul Emery, Roy M. Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L. Hyrich, Annamaria Iagnocco, John D. Isaacs, Joel M. Kremer, Xavier Mariette, Peter Merkel, Eduardo F. Mysler, Peter Nash, Michael T. Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S. Smolen

Summary: This paper is an updated consensus document on the medical use of IL-6 pathway inhibition in the treatment of inflammatory diseases. The document provides comprehensive consensus statements based on systematic literature research and expert opinion, covering various aspects of IL-6 pathway inhibitors, including dosing, indications, and clinical considerations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Immunology

Characterization of age-associated B cells in early drug-naive rheumatoid arthritis patients

Gemma Vidal-Pedrola, Najib Naamane, James A. Cameron, Arthur G. Pratt, Andrew L. Mellor, John D. Isaacs, Dagmar Scheel-Toellner, Amy E. Anderson

Summary: Age-associated B cells (ABCs) are an immune cell subset linked to autoimmunity, infection, and aging. Studies have shown that ABCs in the peripheral blood of patients with early rheumatoid arthritis (eRA) exhibit distinct transcriptional characteristics compared to control groups, and they are found to be abundant in synovial fluid. These activated B cells express chemokine receptors and adhesion molecules that favor inflammation over lymphoid tissue, and they may play a role in autoimmune pathology due to their antigen presentation and pro-inflammatory phenotype.

IMMUNOLOGY (2023)

Article Rheumatology

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

Ryan M. Hum, Pauline Ho, Nisha Nair, Meghna Jani, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L. Hyrich, Darren Plant, Anne Barton

Summary: This study suggests that higher levels of TNF-a inhibitor serum drug levels (SDLs) are associated with good treatment response in fully adherent patients. Interventions to improve SDLs, such as encouraging adherence, may improve treatment response. The identified SDL cut-offs for adalimumab and certolizumab may be useful in clinical practice.

RHEUMATOLOGY (2023)

Review Rheumatology

Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review

Kevin Winthrop, John Isaacs, Leonard Calabrese, Deepali Mittal, Supriya Desai, Jane Barry, Sander Strengholt, James Galloway

Summary: A literature review of clinical trials found that the use of JAK inhibitors for rheumatoid arthritis is associated with opportunistic infections, with herpes zoster being the most common. Higher rates of infections were observed in Asian and Australian populations, as well as with increasing doses of JAK inhibitors.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2023)

Review Engineering, Biomedical

Interplay between biomaterials and the immune system: Challenges and opportunities in regenerative medicine

Daniel Salthouse, Katarina Novakovic, Catharien M. U. Hilkens, Ana Marina Ferreira

Summary: This review highlights the importance of the immune response to biomaterials and discusses challenges and opportunities in the development and standardized assessment of the immune response to biomaterials, including the importance of endotoxin levels. It also explores the properties of biomaterials that impact the host immune response and the use of immunomodulatory biomaterials in regenerative medicine. Finally, a standardized in vitro pathway for evaluating the immune response to biomaterials (hydrogels) and their regenerative potential is proposed to ensure safety, consistency, and reduce costs and animal use.

ACTA BIOMATERIALIA (2023)

Review Immunology

Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations

Kristian C. Williams, Abigail Gault, Amy E. Anderson, Christopher J. Stewart, Christopher A. Lamb, R. Ally Speight, Neil Rajan, Ruth Plummer, Arthur G. Pratt

Summary: Checkpoint inhibitors (CPIs) disrupt immune checkpoint molecules to block regulatory immune signals, but can cause immune-related adverse events (irAEs) similar to autoimmune diseases. Understanding irAE pathobiology may lead to targeted mitigation strategies and predictive biomarkers. This review focuses on irAEs in the gut, skin, and synovial joints, comparing them to immune-mediated diseases. Studies show dysregulation of cytokines, T-cell infiltration, and potential therapeutic opportunities for irAEs.

FRONTIERS IN IMMUNOLOGY (2023)

Article Rheumatology

Surgeon and physiotherapist approaches to operative or non-operative management of people with recurrent patellar dislocation: A case-based UK survey

Lisa Irving, Toby O. Smith, Vipul I. Mandalia, Arthur Pratt, Daniel Dowen

Summary: This study investigated the decision-making of orthopaedic surgeons and physiotherapists regarding surgical or non-operative treatment for patients with recurrent patellar dislocations. The results showed some disparity between the professions on when to perform surgical assessments and non-operative management, with physiotherapists more likely to delay a surgical opinion.

MUSCULOSKELETAL CARE (2023)

Article Rheumatology

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis

Samantha Louise Smith, Sheree Alexander, Nisha Nair, Sebastien Viatte, Stephen Eyre, Kimme L. Hyrich, Ann W. Morgan, Anthony G. Wilson, John D. Isaacs, Darren Plant, Anne Barton

Summary: The study aimed to explore whether the inflammatory protein MRP8/14 can serve as a biomarker for treatment response in rheumatoid arthritis (RA) patients receiving tumor necrosis factor (TNF) inhibitors. The results showed that in the 3-component and 2-component models, patients with high pre-treatment levels of MRP8/14 were 1.92 and 2.03 times more likely to be classified as EULAR responders compared to those with low levels. However, no significant associations were observed in the 4-component model. Conclusion: Apart from its correlation with CRP, there is no evidence to suggest that MRP8/14 explains additional variability in response to TNFi in RA patients beyond CRP alone.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

The Effect of COVID-19 on Medication Adherence in a Rheumatoid Arthritis (BRAGGSS) and Psoriatic Arthritis (OUTPASS) UK Cohort

Philippa D. K. Curry, Hector Chinoy, Meghna Jani, Darren Plant, Kimmie L. Hyrich, Ann W. Morgan, A. G. Wilson, John D. Isaacs, Andrew P. Morris, Anne Barton, James Bluett

JOURNAL OF RHEUMATOLOGY (2023)

Review Rheumatology

Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis

Joshua. L. L. Bennett, Arthur. G. G. Pratt, Richard Dodds, Avan. A. A. Sayer, John. D. D. Isaacs

Summary: Sarcopenia, characterized by the loss of skeletal muscle strength and mass, is commonly associated with rheumatoid arthritis. This review discusses the epidemiology, pathophysiology, and identification of rheumatoid sarcopenia, as well as the therapeutic roles of physical activity, nutrition, and pharmacotherapy. Rheumatoid sarcopenia is highly prevalent (>= 25%) in individuals with rheumatoid arthritis and is associated with increased risk of falls, fractures, and physical disability.

NATURE REVIEWS RHEUMATOLOGY (2023)

Article Rheumatology

Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy

Daniel Maunder, Philip M. Brown, Ben Barron-Millar, Dennis W. Lendrem, Najib Naamane, Jamie Macdonald, Xiao N. Wang, John D. Isaacs, Amy E. Anderson, Ann W. Morgan, Rachel E. Crossland, Sarah L. Mackie, Arthur G. Pratt

Summary: This study evaluated the potential of serum EV miRs as diagnostic and therapeutic biomarkers in early RA and found a novel potential mechanism by which MTX may exert its therapeutic effect in early RA.

RHEUMATOLOGY (2023)

Article Cell Biology

Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes

Kelsey N. S. Thompson, Kevin S. E. Bonham, Nicholas E. J. Ilott, Graham J. Britton, Paula J. Colmenero, Samuel J. J. Bullers, Lauren J. McIver, Siyuan H. Ma, Long H. Nguyen, Andrew Filer, India Brough, Claire Pearson, Caroline Moussa, Vinod H. Kumar, Lilian H. A. Lam, Matthew A. Jackson, April Pawluk, Serafim R. Kiriakidis, Peter C. Taylor, Lucy R. P. Wedderburn, Brian R. Marsden, Stephen P. J. Young, Dan R. G. Littman, Jeremiah J. Faith, Arthur G. Pratt, Paul Bowness, Karim Raza, Fiona Powrie, Curtis Huttenhower

Summary: Musculoskeletal diseases impact 20% of adults globally. The connection between gut microbiome and inflammatory conditions, like arthritis, has not been fully understood. The Inflammatory Arthritis Microbiome Consortium analyzed 440 stool samples and found differential microbiome composition and functional processes in patients with inflammatory arthritis compared to healthy individuals. This research enhances our understanding of how systemic inflammation during arthritis affects the gut ecosystem.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Rheumatology

The student patient alliance: development and formative evaluation of an initiative to support collaborations between patient and public involvement partners and doctoral students

Gwenda Simons, Rebecca Birch, Joanne Stocks, Elspeth Insch, Rob Rijckborst, Georgiana Neag, Heidi Mccolm, Leigh Romaniuk, Claire Wright, Bethan E. Phillips, Simon W. Jones, Arthur G. Pratt, Stefan Siebert, Karim Raza, Marie Falahee

Summary: This paper describes the development and evaluation of the Student Patient Alliance (SPA), a program that connects PPI partners with doctoral students. Both students and their PPI partners reported positive impacts on understanding, motivation, and communication skills. The SPA is valued and likely to enhance students' PPI and public engagement skills and awareness of patients' experiences on a wider scale.

BMC RHEUMATOLOGY (2023)

Article Rheumatology

Number of days required to measure sedentary time and physical activity using accelerometery in rheumatoid arthritis: a reliability study

Ciara D. O'Brien, George Kitas, Fiona D. Rayner, John F. Isaacs, Kenneth G. Baker, Arthur D. Pratt, Christopher Buckley, Karim Raza, Andrew Filer, Stefan Siebert, Iain McInnes, Andrew McGucken, Sally A. M. Fenton, BIOFLARE Consortium

Summary: This study aimed to determine the minimum number of monitoring days required to reliably estimate sedentary time, light-intensity physical activity, and moderate-intensity physical activity in people with Rheumatoid Arthritis (RA) across different levels of disease activity. The results showed that at least 4 monitoring days were required to reliably estimate sedentary time and light-intensity physical activity, while at least 5 monitoring days were required to reliably estimate behaviors across the movement continuum. This information is important for accurately assessing physical activity levels and sedentary behavior in RA patients and can help inform interventions for promoting physical activity and reducing sedentary time.

RHEUMATOLOGY INTERNATIONAL (2023)

No Data Available